Onco Wiki / Rote Flagge

Bestätigte keimlinienpathogene / wahrscheinlich-pathogene Variante in NF1 ODER Erfüllung von NIH/Be...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDRF-NF1-CONFIRMED-CARRIER
ArtWarnhinweis
Statusreviewed 2026-05-19 | pending_clinical_signoff
ErkrankungenDIS-BREAST DIS-GLIOMA-LOW-GRADE DIS-SOFT-TISSUE-SARCOMA
QuellenSRC-NCCN-BREAST-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025

Ursprung der Roten Flagge

BegriffsbestimmungConfirmed germline pathogenic / likely-pathogenic variant in NF1 OR fulfillment of NIH/Bethesda clinical diagnostic criteria for neurofibromatosis type 1 (≥2 of: ≥6 café-au-lait macules >5 mm pre-pubertal or >15 mm post-pubertal, ≥2 neurofibromas or 1 plexiform neurofibroma, axillary/inguinal freckling, optic pathway glioma, ≥2 Lisch nodules, distinctive osseous lesion, FDR with NF1). NF1 is an autosomal-dominant tumor-predisposition syndrome with ~1 in 3000 prevalence — most common single-gene cancer predisposition syndrome. Cancer spectrum: optic pathway glioma (children, ~15-20%), other CNS gliomas (low- and high-grade across the lifespan, ~5-15% adult prevalence), malignant peripheral nerve sheath tumor (MPNST, ~10-15% lifetime, malignant transformation of plexiform neurofibroma — major life-limiting complication), breast cancer in women (lifetime ~18% by age 50, ~50% by age 70 — co...
Klinische RichtungUntersuchung
KategorieSonstige

Logik auslösen

{
  "any_of": [
    {
      "finding": "germline_nf1_pathogenic_variant_confirmed",
      "value": true
    },
    {
      "finding": "nih_nf1_clinical_diagnostic_criteria_met",
      "value": true
    },
    {
      "finding": "germline_nf1_likely_pathogenic_variant",
      "value": true
    }
  ],
  "type": "lab_value"
}

Anmerkungen

Prevention-persona RedFlag for NF1 confirmed-carrier / clinical- diagnostic-criteria-met cohort. Multi-organ surveillance: pediatric ophthalmology q6-12mo to age 8 (optic glioma); whole-body MRI for MPNST surveillance + symptom-driven biopsy of growing/painful/ neurologically-symptomatic plexiform neurofibromas; women: annual mammography from age 30, MRI from age 30-50. STUB pending two-Co- Lead signoff per CHARTER §6.1 dev-mode.

Verwendet von

Anwendungsgebiet

Warnhinweis